Benchmark Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00

Humacyte (NASDAQ:HUMA) had its price objective lowered by Benchmark from $2.00 to $1.00 in a research report report published on Thursday,Benzinga reports. Benchmark currently has a speculative buy rating on the stock.

HUMA has been the topic of a number of other reports. BTIG Research restated a “buy” rating and set a $2.00 price target on shares of Humacyte in a research report on Wednesday. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. HC Wainwright increased their target price on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Finally, TD Cowen decreased their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.11.

Humacyte Price Performance

NASDAQ:HUMA opened at $0.60 on Thursday. The company has a quick ratio of 3.32, a current ratio of 6.21 and a debt-to-equity ratio of 2.07. The firm has a market cap of $163.08 million, a PE ratio of -1.23 and a beta of 2.53. Humacyte has a 12 month low of $0.53 and a 12 month high of $2.55. The company’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.90.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. On average, equities analysts anticipate that Humacyte will post -0.38 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider directly owned 272,713 shares in the company, valued at $245,441.70. This trade represents a 14.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Humacyte during the 2nd quarter valued at about $28,000. Financial Advisors Network Inc. bought a new position in shares of Humacyte in the 2nd quarter valued at about $28,000. Cerity Partners LLC acquired a new stake in shares of Humacyte during the 2nd quarter worth approximately $35,000. Equitable Holdings Inc. acquired a new stake in shares of Humacyte during the 3rd quarter worth approximately $29,000. Finally, Imprint Wealth LLC acquired a new stake in shares of Humacyte during the 3rd quarter worth approximately $33,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

More Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target for Humacyte. Its forecast still anticipates a shift to profitability, with projected positive EPS of $0.09 in fiscal 2029 and $0.31 in fiscal 2030, suggesting potential long-term upside if the company successfully commercializes its products.
• Neutral Sentiment: HC Wainwright’s updated estimates project continued losses through fiscal 2028, followed by profitability in 2029 and 2030. The firm now expects fiscal 2026 EPS of ($0.46), fiscal 2027 EPS of ($0.30), and fiscal 2028 EPS of ($0.07).
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods, including Q3 2026 to ($0.10) from ($0.09), Q4 2026 to ($0.11) from ($0.09), fiscal 2026 to ($0.46) from ($0.37), and fiscal 2027 to ($0.30) from ($0.26). Longer-term estimates were also cut, with fiscal 2029 EPS lowered to $0.09 from $0.20 and fiscal 2030 EPS to $0.31 from $0.50. These revisions indicate expectations for slower financial improvement.
• Negative Sentiment: Humacyte’s latest quarterly results missed expectations: the company reported a loss of $0.16 per share versus the $0.11 consensus loss, while revenue of $0.41 million was well below the $1.04 million estimate. The substantial operating losses and limited revenue reinforce concerns about cash needs and the timing of commercialization.
• Negative Sentiment: Additional bearish coverage is weighing on investor confidence. Benchmark issued a pessimistic forecast for HUMA. Benchmark Issues Pessimistic Forecast for Humacyte Wall Street Zen also downgraded Humacyte to a Strong Sell rating. Humacyte Lowered to Strong Sell Rating by Wall Street Zen

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.